Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 14/20 | 0.66 |
| ▸ | AVPR2 | P30518 | 5/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.40 |
| ▸ | CCR5 | P51681 | 3/20 | 0.37 |
| ▸ | OXTR | P30559 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5000950 | 0.91 | AVPR1A (0.65) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL5000787 | 0.83 | AVPR1A (0.62) | AVPR1AAVPR2KCNH2 | |
| SCHEMBL5000983 | 0.82 | AVPR1A (0.65) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL5102015 | 0.80 | AVPR1A (0.83) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL5102375 | 0.80 | AVPR1A (1.00) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL5007135 | 0.79 | AVPR1A (0.71) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL3400817 | 0.78 | AVPR1A (0.53) | AVPR1AAVPR2KCNH2 | |
| SCHEMBL11961837 | 0.78 | AVPR1A (0.72) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL2512963 | 0.77 | AVPR1A (0.71) | AVPR1AAVPR2KCNH2OXTR | |
| SCHEMBL2511034 | 0.77 | AVPR1A (0.71) | AVPR1AAVPR2KCNH2OXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7456170-B2 | Triazolobenzodiazepines and their use as vasopressin antagonists | PFIZER INC. (US) | 2008-11-25 | — | — | US | claimed |
| US-7456170-B2 | Triazolobenzodiazepines and their use as vasopressin antagonists | PFIZER INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456170-B2 | Triazolobenzodiazepines and their use as vasopressin antagonists | PFIZER INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456170-B2 | Triazolobenzodiazepines and their use as vasopressin antagonists | PFIZER INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070249585-A1 | Triazolobenzodiazepines and Their Use as Vasopressin Antagonists | PFIZER INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249585-A1 | Triazolobenzodiazepines and Their Use as Vasopressin Antagonists | PFIZER INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249585-A1 | Triazolobenzodiazepines and Their Use as Vasopressin Antagonists | PFIZER INC. | 2007-10-25 | — | — | US | disclosed |
| WO-2006021882-A1 | TRIAZOLOBENZODIAZEPINES AND THEIR USE AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249585-A1 | Triazolobenzodiazepines and Their Use as Vasopressin Antagonists | AVPR2, AVPR1A, AVPR1B | AVPR1A 2/4885AVPR2 1/4885KCNH2 864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.